A Systematic pan-cancer analysis of ATIC as a prognostic biomarker in human tumors

Abstract

Abstract Background 5-Aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) has been identified as a potential biomarker for cancer. However, the biological functions and implications of ATIC in pan-cancer context remain largely unexplored. methods We utilized The Cancer Genome Atlas (TCGA) database to acquire RNA-seq and clinical follow-up data for 33 different tumor types. This data was analyzed to investigate the expression patterns and biological functions of ATIC across pan-cancer, encompassing diverse molecular and immune subtypes. The prognostic and diagnostic significance of ATIC in a pan-cancer context was evaluated using Kaplan-Meier and Receiver Operating Characteristic (ROC) curves. Finally, our study specifically focused on Liver Hepatocellular Carcinoma (LIHC) to elucidate the potential mechanisms underlying ATIC's role in LIHC. results ATIC expression was found to be up-regulated in a broad spectrum of tumor tissues, exhibiting significant variability across different molecular and immune subtypes. Furthermore, ATIC demonstrated high accuracy in cancer prediction and was notably correlated with the prognosis of various cancers. Specifically, in Liver Hepatocellular Carcinoma (LIHC), ATIC's expression was significantly linked to clinicopathologic features, a range of cancer-related pathways, the extent of immune cell infiltration, and m6A modifications. conclusion ATIC could potentially serve as a molecular biomarker for both the diagnosis and prognosis of pan-cancer. Additionally, it may play a significant role in the progression and metastasis of LIHC through various mechanisms.